Cell and gene therapy firm Abeona Therapeutics Inc., of New York, will focus its resources on the phase III VIITAL study of EB-101 for recessive ...
https://www.google.com/url?rct=j&sa=t&url=https://www.bioworld.com/articles/517472-other-news-to-note-for-april-1-2022&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNEQP5Std_Zu9Y3aMtKk3KMwZSSgYA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.